KT-621 BROADEN2 Phase 2b topline data in atopic dermatitis
Kymera expects to report results from its Phase 2b (enrollment complete) study of KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis in Q4 2026 (Oct–Dec) (no exact date yet). This is the first look at whether the drug did what the company hoped.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Kymera Therapeutics, Inc. KYMR
- Drug
- KT-621 (oral STAT6 degrader)
- For
- moderate-to-severe atopic dermatitis
- Stage
- Phase 2b (enrollment complete)
- When
- Q4 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Enrollment completed ~6 months early; topline data accelerated to "by year-end 2026" from prior mid-2027 guidance. ~200 patients, three doses vs placebo, 16 weeks.
- Checked
- Checked by a person when it was added
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Kymera expects to report results from its Phase 1 study of KT-579 (oral IRF5 degrader) for immunology (lupus and other autoimmune diseases) in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- KT-579 Phase 1 healthy volunteer data · Clinical trial results (readout / topline data)
- Drug
- KT-579 (oral IRF5 degrader)
- For
- immunology (lupus and other autoimmune diseases)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Phase 1 healthy volunteer trial ongoing with data expected in 4Q26; Phase 1b lupus proof-of-concept trial planned soon after.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KT-621 Phase 3 initiation in atopic dermatitis, expected in the first half of 2027 (no exact date yet). A company milestone for Kymera (KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis): a step in the program rather than a decision or a data readout.
More details
- Entry
- KT-621 Phase 3 initiation in atopic dermatitis · Company milestone
- Drug
- KT-621 (oral STAT6 degrader)
- For
- moderate-to-severe atopic dermatitis
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Subject to regulator discussions, company expects to initiate Phase 3 AD trials by mid-2027.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead IND filing for KT-200 CDK2 degrader, expected during 2027 (no exact date yet). A company milestone for Kymera (KT-200 for oncology (CDK2)): a step in the program rather than a decision or a data readout.
More details
- Entry
- Gilead IND filing for KT-200 CDK2 degrader · Company milestone
- Drug
- KT-200
- For
- oncology (CDK2)
- Stage
- Preclinical
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Aug 5, 2026): Gilead exercised its exclusive license option on KT-200 in April 2026 ($45M milestone) and plans an IND filing in 2027. Same PR reiterates KT-621 BROADEN2 AD data by year-end 2026, Ph3 AD start by mid-2027, BREADTH asthma data late 2027, and KT-579 Ph1 HV data in 4Q26 (all already tracked).
- Checked
- Checked by a person when it was added
- Verify it
- Source: manilatimes.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page